Matt Davidson Sells 13,212 Shares of Verrica Pharmaceuticals Inc (NASDAQ:VRCA) Stock

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) major shareholder Matt Davidson sold 13,212 shares of the company’s stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $11.58, for a total value of $152,994.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Matt Davidson also recently made the following trade(s):

  • On Monday, July 8th, Matt Davidson sold 12,529 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $11.27, for a total value of $141,201.83.
  • On Tuesday, July 2nd, Matt Davidson sold 33,521 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $11.63, for a total value of $389,849.23.
  • On Tuesday, June 25th, Matt Davidson sold 210 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.04, for a total value of $2,108.40.
  • On Thursday, June 13th, Matt Davidson sold 2,131 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $9.65, for a total value of $20,564.15.
  • On Tuesday, June 11th, Matt Davidson sold 4,345 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $8.49, for a total value of $36,889.05.
  • On Thursday, June 6th, Matt Davidson sold 5,507 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $7.27, for a total value of $40,035.89.
  • On Monday, June 3rd, Matt Davidson sold 4,110 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $7.36, for a total value of $30,249.60.
  • On Wednesday, May 29th, Matt Davidson sold 2,100 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $8.41, for a total value of $17,661.00.
  • On Thursday, May 23rd, Matt Davidson sold 2,422 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $8.80, for a total value of $21,313.60.
  • On Monday, May 20th, Matt Davidson sold 1,800 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $8.95, for a total value of $16,110.00.

VRCA opened at $11.00 on Friday. Verrica Pharmaceuticals Inc has a 52-week low of $6.44 and a 52-week high of $19.10. The company has a market capitalization of $282.79 million and a price-to-earnings ratio of -7.80. The stock’s 50-day moving average is $9.52.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its earnings results on Tuesday, May 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.02). On average, equities analysts forecast that Verrica Pharmaceuticals Inc will post -1.36 EPS for the current year.

VRCA has been the topic of several analyst reports. Zacks Investment Research lowered Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 11th. HC Wainwright upped their target price on Dova Pharmaceuticals from $18.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, June 27th.

A number of large investors have recently added to or reduced their stakes in the business. New York State Common Retirement Fund bought a new stake in Verrica Pharmaceuticals in the fourth quarter valued at approximately $28,000. Bank of New York Mellon Corp raised its stake in Verrica Pharmaceuticals by 39.1% in the fourth quarter. Bank of New York Mellon Corp now owns 16,662 shares of the company’s stock valued at $136,000 after buying an additional 4,681 shares during the period. Northern Trust Corp raised its stake in Verrica Pharmaceuticals by 7.5% in the fourth quarter. Northern Trust Corp now owns 67,028 shares of the company’s stock valued at $546,000 after buying an additional 4,689 shares during the period. Asymmetry Capital Management L.P. raised its stake in Verrica Pharmaceuticals by 12.0% in the first quarter. Asymmetry Capital Management L.P. now owns 70,458 shares of the company’s stock valued at $762,000 after buying an additional 7,576 shares during the period. Finally, Geode Capital Management LLC raised its stake in Verrica Pharmaceuticals by 31.7% in the fourth quarter. Geode Capital Management LLC now owns 36,906 shares of the company’s stock valued at $300,000 after buying an additional 8,885 shares during the period. Hedge funds and other institutional investors own 34.31% of the company’s stock.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.

Read More: Trading Ex-Dividend Strategy

Insider Buying and Selling by Quarter for Verrica Pharmaceuticals (NASDAQ:VRCA)

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.